Yeztugo Side Effects

Generic name: lenacapavir

Medically reviewed by Drugs.com. Last updated on Jan 5, 2025.

Note: This document provides detailed information about Yeztugo Side Effects associated with lenacapavir. Some dosage forms listed on this page may not apply specifically to the brand name Yeztugo.

Applies to lenacapavir: oral tablet.

Other dosage forms:

• subcutaneous solution

Precautions

It is very important that your doctor check your progress at regular visits to make sure that this medicine is working properly. Blood tests may be needed to check for unwanted effects.

Do not use this medicine together with carbamazepine (Tegretol®), phenytoin (Dilantin®), rifampin (Rifadin®), or St. John’s wort.

Your immune system may get stronger when you start using HIV medicines. Tell your doctor right away if you notice any changes in your health. Sometimes the immune system will start to fight infections that were hidden in your body, including pneumonia, herpes, or tuberculosis. Autoimmune disorders (eg, Graves disease, polymyositis, and Guillain-Barré syndrome) may also occur.

Do not take other medicines unless they have been discussed with your doctor. This includes prescription or nonprescription (over-the-counter [OTC]) medicines and herbal or vitamin supplements.

Serious side effects of Yeztugo

Along with its needed effects, lenacapavir (the active ingredient contained in Yeztugo) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking lenacapavir:

See also:

For healthcare professionals

Applies to lenacapavir: oral tablet, subcutaneous solution.

General adverse events

The most common adverse reactions reported in at least 3% patients were nausea and injection site reactions.^[Ref]

Gastrointestinal

• Common (1% to 10%): Nausea^[Ref]

Hepatic

• Common (1% to 10%): Increased alanine aminotransferase (ALT), increased aspartate aminotransferase (AST), increased direct bilirubin^[Ref]

Local

• Very common (10% or more): Injection site reactions (65%) [include swelling (36%), pain (31%), erythema (31%), nodule (25%), induration (15%), pruritus (6%), extravasation (3%) discomfort (1%), mass (3%), hematoma (1%), edema (1%) and ulcer (1%)]^[Ref]

Four percent patients experienced Grade 3 ISRs (erythema, pain, swelling)^[Ref]

Metabolic

• Common (1% to 10%): Glycosuria, hyperglycemia, proteinuria^[Ref]

Musculoskeletal

• Very common (10% or more): Increased creatinine (13%)^[Ref]

Further information

Yeztugo side effects can vary depending on the individual. Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Note: Medication side effects may be underreported. If you are experiencing side effects that are not listed, submit a report to the FDA by following this guide.

Medical Disclaimer